Unicycive Therapeutics (UNCY) Competitors $4.39 -0.25 (-5.39%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. CYRX, IVA, OCGN, PRTA, HRTX, AURA, TKNO, RCKT, AVTE, and GLUEShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include CryoPort (CYRX), Inventiva (IVA), Ocugen (OCGN), Prothena (PRTA), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), Aerovate Therapeutics (AVTE), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors CryoPort Inventiva Ocugen Prothena Heron Therapeutics Aura Biosciences Alpha Teknova Rocket Pharmaceuticals Aerovate Therapeutics Monte Rosa Therapeutics CryoPort (NASDAQ:CYRX) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Which has more volatility and risk, CYRX or UNCY? CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Do institutionals and insiders believe in CYRX or UNCY? 92.9% of CryoPort shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 10.0% of CryoPort shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is CYRX or UNCY more profitable? Unicycive Therapeutics has a net margin of 0.00% compared to CryoPort's net margin of -50.15%. CryoPort's return on equity of -11.03% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CryoPort-50.15% -11.03% -5.54% Unicycive Therapeutics N/A -277.30%-61.53% Do analysts rate CYRX or UNCY? CryoPort currently has a consensus target price of $11.00, indicating a potential upside of 47.24%. Unicycive Therapeutics has a consensus target price of $60.00, indicating a potential upside of 1,266.74%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Which has better earnings and valuation, CYRX or UNCY? Unicycive Therapeutics has lower revenue, but higher earnings than CryoPort. CryoPort is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoPort$228.38M1.64-$114.76M-$2.34-3.19Unicycive Therapeutics$680K81.60-$36.73M-$5.10-0.86 Does the media favor CYRX or UNCY? In the previous week, Unicycive Therapeutics had 3 more articles in the media than CryoPort. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 8 mentions for CryoPort. CryoPort's average media sentiment score of 0.66 beat Unicycive Therapeutics' score of 0.24 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryUnicycive Therapeutics beats CryoPort on 9 of the 16 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.49M$2.43B$5.50B$9.00BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-0.868.8826.5720.02Price / Sales81.60672.33415.46120.95Price / CashN/A151.5836.1356.90Price / Book6.104.618.065.50Net Income-$36.73M$31.16M$3.15B$248.50M7 Day Performance-26.09%0.51%1.72%2.61%1 Month Performance-42.46%7.63%3.92%5.42%1 Year Performance-10.41%1.44%35.02%20.76% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.1608 of 5 stars$4.39-5.4%$60.00+1,266.7%-3.3%$55.49M$680K-0.869CYRXCryoPort2.0901 of 5 stars$6.56+3.0%$11.00+67.7%+20.4%$319.37M$228.38M0.001,186News CoverageIVAInventiva3.4942 of 5 stars$3.34+1.5%$10.40+211.5%+4.6%$314.73M$9.95M0.00100Positive NewsGap UpOCGNOcugen1.3436 of 5 stars$0.98-7.4%$6.00+511.6%-42.5%$309.55M$4.05M0.0080High Trading VolumePRTAProthena3.2049 of 5 stars$6.06+5.9%$31.50+419.8%-69.0%$307.89M$135.16M0.00130HRTXHeron Therapeutics3.9507 of 5 stars$2.11+5.5%$5.00+137.0%-21.5%$305.13M$144.29M0.00300AURAAura Biosciences2.3952 of 5 stars$6.15+1.8%$22.00+257.7%-9.7%$303.62MN/A0.0050TKNOAlpha Teknova3.0395 of 5 stars$5.28-5.0%$8.50+61.0%+313.8%$297.13M$37.74M0.00240News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8897 of 5 stars$2.63-2.6%$18.60+607.2%-85.4%$288.32MN/A0.00240AVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-82.4%$286.66MN/A-3.3120Gap DownHigh Trading VolumeGLUEMonte Rosa Therapeutics1.8118 of 5 stars$4.64+0.2%$15.50+234.1%+31.8%$284.79M$75.62M57.8890Positive News Related Companies and Tools Related Companies CryoPort Alternatives Inventiva Alternatives Ocugen Alternatives Prothena Alternatives Heron Therapeutics Alternatives Aura Biosciences Alternatives Alpha Teknova Alternatives Rocket Pharmaceuticals Alternatives Aerovate Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
